zepbound glp 1 agonist GLP-1 weight-loss drugs: PA, NJ poison control centers see more calls Zepbound leads to more weight

Niraparib showed promising activity in preclinical models and phase I clinical trials, achieving its pharmacodynamic target for PARP inhibition in epithelial ovarian cancer, particularly in patients who have responded to platinum-based chemotherapy 167 (Fig

Diabetic and corticosteroid-impaired models are used to characterize these mechanisms under conditions of disrupted tissue repair

Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinsons disease

While experimental findings point to diverse biological actions, mechanisms remain uncertain and outcomes appear context-dependent